PubMed Health⌕ Search

Biomedical subjects

J de Sousa

Publications and source records attributed to J de Sousa.

14 recordsLinked to original sources
PubMed2001

Basal cell carcinoma on the vermilion border of the lip: a study of six cases.

BACKGROUND: The vermilion border of the lower lip is a frequent location of squamous cell carcinoma (SCC), but it is very rarely mentioned within the published series of basal cell carcinomas (BCCs). OBJECTIVE: We present 6 cases of BCC involving either mainly or exclusively the vermilion border of a lip. METHODS: We reviewed from our files all the cases of BCC diagnosed in a period of 11 years. RESULTS: A number of 3,477 BCCs were histologically diagnosed in that period; 2,872 (82.6%) of them were located on the head, and 66 (2.3%) of the latter (1.9% of all BCCs) were on the lips. In 6 cases, the neoplasm involved either mainly or exclusively the vermilion border of either the lower (5 cases) or the upper (1 case) lip. CONCLUSION: Not every carcinoma of the vermilion border of the lip is a SCC.

Adult↗
PubMed2001

[Prevention of complications: a forgotten aspect of therapy? arrhythmia complication in heart failure].

Heart failure has a high prevalence in the western world: 1-1.5% in the general population and 2-5% in patients above 65 years old. The association with cardiac dysarrhythmia is very common: 20-30% of patients have atrial fibrillation and significant ventricular arrhythmias occur in 50%. The pathophysiology of cardiac arrhythmias is multifactorial, including reentry, increased automaticity and triggered activity. Several prognostic factors have been described in patients with coronary artery disease, however, the two more important are the functional class and the severity of left ventricular dysfunction. In order to prevent disarrhythmic complications, the appropriate treatment of heart failure and of the underlying cardiac disease are very important. Class III antiarrhythmic drugs and the implantable cardioverter-defibrillator are increasingly used as primary (in high risk patients) or secondary prophylactic agents.

Anti-Arrhythmia Agents↗
PubMed1999

[In recurrent atrial fibrillation should a sinus rhythm always try to be maintained? How?].

This paper presents the therapeutic options for recurrent paroxysmal atrial fibrillation. In the majority of patients, sinus rhythm should be maintained in order to improve cardiac function and decrease the risk of systemic embolism. Therapeutic options include serial pharmacological agents (with repeated external cardioversion) or non-pharmacological therapy: catheter or surgical ablation and atrial pacing.

Anti-Arrhythmia Agents↗
PubMed1997

[Incessant atrial tachycardia and peripartum cardiomyopathy--a therapeutic challenge].

Peripartum cardiomyopathy is an uncommon cause of heart failure but with serious prognosis. We report the case of a patient with peripartum cardiomyopathy presenting acute heart failure (severe biventricular systolic failure) and incessant atrial tachycardia, a rare arrhythmia difficult to control, that was responsible for cardiogenic shock, fetus death and multiple organ failure: renal failure (hemodialysis during 17 days), respiratory and hepatic failure and ischemic acute cholecystitis (treated surgically). After emergency cesarean section, heart rate control was obtained only after administering verapamil. Progressive clinical improvement with total recovery of hepatic and renal functions followed under treatment with vigorous multiple organ support. Six months after referral, the patients is doing well with normal daily life controlled with conventional therapy for heart failure, in stable sinus rhythm. Echocardiography shows a dilated left ventricle with partial resolution of systolic dysfunction rhythm. Echocardiography shows a dilated left ventricle with partial resolution of systolic dysfunction. The use of verapamil in severe biventricular systolic failure is discussed.

Cardiomyopathies↗
PubMed1996

[Idiopathic ventricular fibrillation: apropos of 2 clinical cases].

We describe two patients with idiopathic ventricular fibrillation recently evaluated to whom it was implanted a cardioversor desfibrillator system. It is our purpose to make a brief review of the etiology, diagnostic procedures, therapy and prognosis of this clinical entity, which is an important rare cause of sudden cardiac death.

Adult↗
PubMed1994

[Efficacy and safety of adenosine triphosphate in the control of supraventricular paroxysmal tachycardia].

Our purpose was to assess the efficacy and safety of intravenous ATP for the acute termination of paroxysmal supraventricular tachycardia. There were 14 women and 10 men, aged 38 +/- 15 years. Three patients had evidence of structural heart disease (Ebstein's anomaly associated to atrial septal defect, operated mitral stenosis with insertion of a mechanical heart valve and CAD respectively). Twelve patients had Wolff-Parkinson-White syndrome and another had undergone surgical ablation of an accessory pathway. At the time of electrophysiologic testing, ATP was administered during episodes of paroxysmal supraventricular tachycardia, via a central vein, in incremental doses of 5, 10 and 20 mg followed by a flush of 10 c.c. of isotonic saline. The mechanism of the arrhythmia was orthodromic AV reentrant tachycardia in 19 (79%), AV nodal reentrant tachycardia in 4 (16.6%) and atrial tachycardia in one patient. The mean frequency of the tachycardia was 174 +/- 33 b.p.m. A dose of 5 mg was effective in 16 patients (66%), 5 required 10 mg and two required 20 mg for termination of the tachycardia. In the patient with atrial tachycardia ATP was not effective. The average time after injection to termination of the arrhythmia was 16 +/- 8 seconds. Orthodromic AV reentrant tachycardia was interrupted in the AV node limb in all but one patient and AV nodal reentry was terminated in the "slow-pathway" in three of the four patients. Nine patients had premature ventricular complexes, isolated or in couplets, after the termination of the SVT. Three patients had immediate recurrence of the SVT.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenosine Triphosphate↗
PubMed1989

A possible autocrine role for interleukin-6 in two lymphoma cell lines.

Interleukin-6 (IL-6) is a growth factor with diverse biologic activity. Originally described as a T-cell product that enhances immunoglobulin (Ig) secretion in antigen-stimulated B cells, it also affects the growth of T cells, plasmacytomas, hybridomas, and hematopoietic stem cells. We report the expression and secretion of IL-6 by two lymphoma cell lines, OCI-LY3 and OCI-LY12. Addition of recombinant IL-6 stimulated their growth, whereas addition of polyclonal anti-recombinant IL-6 (anti-rIL-6) had a marked inhibitory effect on proliferation. These results suggest an autocrine role for IL-6 in the growth of these lymphoma cells in culture.

Blotting, Northern↗
PubMed1989

The T-cell receptor delta chain locus is disrupted in the T-ALL associated t(11;14)(p13;q11) translocation.

Two T-ALL patients carrying a t(11;14)(p13;q11) translocation were analyzed. Southern blotting experiments demonstrated that both patients had rearranged their J delta genes and that the translocation involved the delta locus in both cases. In one patient, cloning, restriction mapping, and sequencing showed that the translocation occurred on a D delta 1-D delta 2-J delta 2 rearranged gene. In addition, the rearrangement on chromosome 11 occurred in both patients within a segment of less than or equal to 2 kb showing the presence in this region of a point of recurrent recombination.

Base Sequence↗
PubMed1988

The isolation of the human delta chain gene and its expression in normal T cells and T cell leukemias.

In this paper we describe a gene that lies 85 kb 5' of the constant region of the human alpha chain and some 30-50 kb 3' of the alpha chain V region (H. Griesser, unpublished observation). This gene undergoes somatic recombination and is transcribed in thymocytes, PHA-stimulated peripheral blood T cells, and some T cell leukemic cell lines. Sequence analysis revealed that the gene has a structure similar to that of immunoglobulin and other T cell antigen receptor genes. Comparison of the sequence to a mouse gene found in a similar location revealed 80% homology at the protein level. Recently, M. Davis and A. Weiss (personal communication) have demonstrated that the protein product of the mouse gene is the delta chain gene. Thus, the gene described in this paper represents the human homolog of the delta chain gene of the T cell antigen receptor.

Amino Acid Sequence↗
PubMed1986

Age-related decrease in ultraviolet induced DNA repair in neurons but not in lymph node cells of inbred mice.

DNA repair capacity was measured, as UV induced, unscheduled DNA synthesis (UDS), in cells of the nervous and immune system of three mouse strains, as a function of age. The strains examined were DBA/1J, C57B1/6J and SJL/J. For dorsal root ganglion neurons of strain DBA/1J, aged 97-98 weeks, a significant decline in UDS of 53% at 20 J/m2 and 73% at 40 J/m2, respectively, was measured, when compared to mice aged 17-18 weeks. Similarly, neurons from C57B1/6J mice, aged 115-116 weeks, showed significant, age dependent decreases of 31% at 20 J/m2 and 40% at 40 J/m2, respectively, compared to mice aged 7-8 weeks. In lymph node cells of all three strains employed, no significant age related decreases in UDS were detected. While the complexity of processes involved in DNA repair makes conclusive interpretation of the results precarious, the results obtained for post-mitotic cells of the nervous system, may be viewed as compatible with the DNA repair hypothesis of ageing.

Aging↗